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Carbonyl reductase 1 catalyzes 
20β-reduction of glucocorticoids, 
modulating receptor activation and 
metabolic complications of obesity
Ruth A. Morgan1,2, Katharina R. Beck3, Mark Nixon  1, Natalie Z. M. Homer  4, Andrew A. 
Crawford1,5, Diana Melchers6, René Houtman6, Onno C. Meijer7, Andreas Stomby8, Anna 
J. Anderson1, Rita Upreti1, Roland H. Stimson1, Tommy Olsson8, Tom Michoel  9, Ariella 
Cohain10, Arno Ruusalepp11,12,13, Eric E. Schadt  10, Johan L. M. Björkegren10,11,12,13,14, Ruth 
Andrew  1,4, Christopher J. Kenyon1, Patrick W. F. Hadoke1, Alex Odermatt  3, John A. Keen2 
& Brian R. Walker1,4
Carbonyl Reductase 1 (CBR1) is a ubiquitously expressed cytosolic enzyme important in exogenous 
drug metabolism but the physiological function of which is unknown. Here, we describe a role for 
CBR1 in metabolism of glucocorticoids. CBR1 catalyzes the NADPH- dependent production of 
20β-dihydrocortisol (20β-DHF) from cortisol. CBR1 provides the major route of cortisol metabolism 
in horses and is up-regulated in adipose tissue in obesity in horses, humans and mice. We 
demonstrate that 20β-DHF is a weak endogenous agonist of the human glucocorticoid receptor (GR). 
Pharmacological inhibition of CBR1 in diet-induced obesity in mice results in more marked glucose 
intolerance with evidence for enhanced hepatic GR signaling. These findings suggest that CBR1 
generating 20β-dihydrocortisol is a novel pathway modulating GR activation and providing enzymatic 
protection against excessive GR activation in obesity.
Carbonyl reductase 1 is a member of the short chain dehydrogenase/reductase family and is most commonly 
studied for its role in exogenous drug metabolism, particularly the conversion of chemotherapeutic drug doxo-
rubicin to cardiotoxic danurubicin1, 2. Significant effort has gone into developing inhibitors of this enzyme which 
could be administered as an adjunct to doxorubicin therapy and thus reduce cardiac side effects3–5. There is also 
marked biological variation in expression of the CBR1 protein between ethnicities6 and following exposure to 
environmental agents such as cigarette smoke7 and flavonoids8. However the physiological role of this enzyme is 
unknown. Here we describe a novel role for CBR1 in glucocorticoid metabolism.
Glucocorticoids act through ubiquitous glucocorticoid receptors (GR) and cell-specific mineralocorticoid 
receptors (MR) to modulate, for example, fuel metabolism, inflammation and salt and water balance. Plasma 
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glucocorticoid concentrations are controlled by the hypothalamic-pituitary-adrenal axis, which balances adrenal 
secretion of glucocorticoids against their clearance from the circulation by intracellular enzymes, predominantly 
active in the liver and kidney. These enzymes also modulate intracellular glucocorticoid concentrations inde-
pendently of plasma concentrations, thereby conferring tissue-specific control of GR and MR activation. For 
example, in mineralocorticoid-responsive tissues such as the kidney and colon, MR are protected from exposure 
to the high-affinity ligand cortisol by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2)9, which converts cor-
tisol to inert cortisone; inhibition of 11β-HSD2 results in cortisol-dependent excessive MR activation and hyper-
tension. In contrast, in glucocorticoid-responsive tissues such as liver and adipose, cortisol is regenerated from 
cortisone by 11β-HSD type 1 (11β-HSD1) thereby amplifying GR activation10; inhibition of 11β-HSD1 improves 
glucose tolerance in patients with type 2 diabetes11. Further modulation of receptor activation may be conferred 
by generation of glucocorticoid metabolites which retain activity at corticosteroid receptors. For example, hepatic 
5α-reduction is the predominant clearance pathway for cortisol in humans but the product of this pathway, 
5α-tetrahydrocortisol (5α-THF), is a selective GR modulator which may contribute to anti-inflammatory sig-
naling12; inhibition of 5α-reductase type 1 results in glucose intolerance and liver fat accumulation, likely due 
to increased cortisol action in liver or skeletal muscle13. In humans and in rodent models, obesity is associated 
with tissue-specific dysregulation of cortisol metabolism, for example increased 5α-reductase activity and altered 
11β-HSD1 activity14.
We embarked on an investigation of cortisol metabolism in domesticated horses, for whom obesity is a grow-
ing problem15 and discovered that the predominant metabolite of cortisol (F) in this species is 20β-dihydrocortisol 
(20β-DHF), which is increased in obesity. 20β-DHF has previously been identified in equine16 and human17 
urine. Increased urinary excretion of 20β-DHF has been associated with Cushing’s disease18 and hypertension19 in 
humans. In this study we: dissected pathway producing 20β-DHF in horses, humans and mice; documented the 
enzyme responsible as carbonyl reductase 1 (CBR1); discovered that 20β-DHF modulates GR; and demonstrated 
the metabolic consequences of inhibiting CBR1.
Results
20β-Dihydrocortisol is a metabolite of cortisol in horses and humans and its urinary excretion is 
increased in obesity. Urine, blood and tissue were collected from healthy (n = 14) and obese (n = 14) horses 
at post-mortem (see Supplementary Table S1 for clinical characteristics). Glucocorticoids were extracted and 
quantified using GC-MS/MS (urine) or LC-MS/MS (tissue and plasma). 20β-DHF accounted for approximately 
60% of total glucocorticoid metabolite urinary excretion in healthy horses, and was increased in obese horses 
(Fig. 1A). Plasma 20β-DHF, but not cortisol, concentrations were also increased in obese horses (Fig. 1B). In 
Figure 1. 20β-Dihydrocortisol (20β-DHF) is an abundant cortisol metabolite which is increased in plasma and 
urine of obese horses. (A) Obese horses excreted significantly more urinary β-cortol, β-cortolone and 20β-DHF 
than lean horses as measured by GC-MS/MS. (B) Plasma 20β-DHF concentrations were significantly higher in 
obese horses compared to lean horses. (C) Hepatic 20β-DHF concentrations did not differ between lean and 
obese horses. (D) Visceral adipose 20β-DHF concentrations did not differ between lean and obese horses. Data 
are mean ± SEM, n = 14/group, *P < 0/05.
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visceral adipose tissue and liver, cortisol and 20β-DHF concentrations were measurable but not different between 
lean and obese horses (Fig. 1C–D).
Twenty-four hour urine samples were collected from healthy lean men (mean age 37.7 ± 15.9 years), and from 
obese men with and without type 2 diabetes (mean age 51.1 ± 14.9 years). As previously reported, the human 
urinary cortisol metabolite profile was dominated by products of 5α- and 5β- reduction, β-cortol in particular17, 
and total metabolite excretion was increased in obesity20 (Supplementary Fig. S1). 20β-DHF was observed in 
human urine, accounting for approximately 3% of total urinary cortisol metabolites (Supplementary Fig. S1), 
and 20β-DHF excretion was increased in obesity (Fig. 2A), independently of the presence of diabetes, but was 
not disproportionately increased compared with other measured cortisol metabolites (see Supplementary Fig. S1 
for metabolite pathways). 20β-DHF was also readily detected in plasma from healthy lean men at similar levels to 
corticosterone (Fig. 2B), but was not altered in obesity.
Carbonyl reductase 1 converts cortisol to 20β-dihydrocortisol and is increased in equine, 
murine and human obesity. The enzyme responsible for 20β-DHF production was previously unknown. 
Carbonyl reductase 1 (CBR1) is a ubiquitously expressed short-chain dehydrogenase known for its role in xeno-
biotic metabolism21. Cortisol is reported as a substrate of CBR1 but its product has not been identified21. We 
found that recombinant human CBR1 converted cortisol to 20β-DHF in the presence of NADPH at a rate of 
1.2 ± 0.4 ng/mg CBR1 protein per minute (1 μM cortisol substrate). Moreover, CBR1 accounts for equine pro-
duction of 20β-DHF, which was the predominant metabolite in equine liver homogenate incubated with cortisol 
(Supplementary Fig. S2A), since this reaction was blocked by co-incubation with the CBR1 inhibitor quercetin in 
equine liver cytosol (Supplementary Fig. S2B). 20β-DHF was not produced by incubation of equine liver micro-
somes with cortisol.
CBR1 is highly expressed in gut, liver, adipose and renal tissue of mice and humans (http://www.proteinatlas.
org/ENSG00000159228-CBR1/tissue), the expression profile of horses has not been reported. We chose to exam-
ine the effect of obesity on expression of CBR1 in liver and adipose tissue. Hepatic CBR1 mRNA was not altered 
in obesity in horses or mice but CBR1 mRNA was increased in adipose tissue of obese horses (Fig. 3A). CBR1 
mRNA was also higher in high-fat fed mice (Fig. 3B) and in visceral adipose tissue from obese compared with 
lean men (n = 8/group, Fig. 3C).
Common functional genetic variants in the CBR1 locus predict metabolic disturbances in 
obesity. We used an expression quantitative trait loci (eQTL) approach in the STARNET dataset22 to test 
whether any SNPs in the CBR1 locus had a functional effect on hepatic or visceral adipose CBR1 expression, 
and then tested their association with phenotypic traits in publicly accessible datasets using MR-Base23. There 
were no eQTLs which influenced visceral adipose expression of CBR1 but eQTLs were identified in liver. Further 
analyses suggested that SNPs associated with higher CBR1 expression in the liver were causally associated with 
higher fasting glucose (beta 0.01, se <0.01, p = 0.02), higher glycated haemoglobin (beta 0.01, se <0.01, p = 0.01) 
(Supplementary Table S5). There was no evidence that CBR1 expression was causally associated with fasting 
insulin, HOMA-B or HOMA-IR (p > 0.2), although there was suggestive evidence that higher CBR1 expression 
causes lower body fat (beta −0.01, se 0.01, p-0.06). In addition to these observations in population based cohorts, 
eQTLs of CBR1 in liver were associated with BMI in the STARNET study participants (rs2835288, p = 5.7E-4). 
The eQTL rs2835288 had a negative effect on BMI (r = −0.13) but a positive effect on CBR1 liver expression 
(r = 0.43); accordingly CBR1 liver expression and BMI were negatively correlated (r = −0.093, p = 0.03). Using a 
conservative causal inference test24 there was suggestive evidence (p = 0.07) that expression of CBR1 in liver was 
causal for variation in BMI.
Figure 2. Urinary 20β-DHF is detectable in human urine and increased in obesity. (A) Obese (BMI >25, 
n = 37) humans excrete 20β-DHF at higher levels than lean (BMI <25, n = 15) humans. (B) 20β-DHF is readily 
detectable in human plasma but concentrations are not altered in obesity (n = 10/group). Plasma cortisol and 
corticosterone were not different between the groups. Data are mean ± SEM, *P < 0/05.
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20β-DHF activates glucocorticoid receptors. Given apparently contradictory associations of genetically 
high CBR1 activity with metabolic dysfunction but not obesity in humans, and the association of CBR1 expres-
sion and activity with obesity in multiple species, we investigated the interaction of 20β-DHF with GR in order to 
predict consequences of elevated CBR1 for GR activation.
Computational evaluation of the interactions formed by 20β-DHF with the GR ligand binding site using 
docking calculations revealed a similar binding pose compared to cortisol (Fig. 4A). Both ligands formed 
hydrogen-bonds (H-bonds) similar in length with the same amino acid residues (Arg611, Gln570, Asn564 and 
Thr739). The only difference observed was the hydroxyl group of 20β-DHF at position 20 representing a hydrogen 
bond donor instead of the carbonyl group of cortisol at the same position serving as hydrogen bond acceptor. 
Human epithelial A549 cells expressing endogenous GR and SF9 and HEK293 cells transfected with human 
GR were used to investigate 20β-DHF as an endogenous ligand of GR. In binding studies, unlabeled 20β-DHF 
displaced dexamethasone from GR in SF9 cell lysate preparations but only at 1000-fold higher concentration 
than cortisol (Fig. 4B). Nonetheless, transfection of HEK293 cells with GFP-GR showed that 20β-DHF induced 
nuclear translocation of GR within 30 minutes (Fig. 4C).
In functional studies, 20β-DHF was a weak agonist of GR. In A549 cells MMTV promoter-induced lucif-
erase activity, indicative of GR activation, was only partially induced by 20β-DHF at high concentration (2.5 μM; 
Fig. 4D). However, endogenous GR-responsive genes glucocorticoid-induced leucine zipper (GILZ), insulin-like 
growth factor binding protein 1 (IGFBP1), dual specificity phosphatase 1 (DUSP1) and FK506-binding protein 
51 (FKBP51) were all up-regulated by 20β-DHF in a concentration-dependent manner (Fig. 4E) and to a similar 
maximum as cortisol, albeit at substantially higher concentrations than cortisol. Similar dose-response relation-
ships were seen comparing the effects of cortisol and 20β-DHF in preventing IL-1β induction by TNFα in A549 
cells (Fig. 4F).
Co-regulator recruitment by GR on binding 20β-DHF was assessed by microarray assay for real-time 
co-regulator-nuclear receptor interaction (MARCoNI) with the GR agonist dexamethasone used as a positive 
control25. Under these conditions, 20β-DHF-activated GR recruited approximately 36% of the co-regulators 
recruited by dexamethasone (Fig. 5 and supplementary Excel file).
Pharmacological inhibition of Cbr1 in mice results in increased hepatic GR activation and 
worsens the metabolic effects of high-fat feeding. Knowing that both cortisol and 20β-DHF might 
amplify GR activation, we sought to test the effects of Cbr1 inhibition in mice to determine whether increas-
ing the substrate/product balance would increase or decrease GR activation. Unlike horses and humans, mice 
produce corticosterone (B) rather than cortisol as their major glucocorticoid. To validate the use of murine 
models to study the CBR1/20β-dihydroglucocorticoid pathway, preparatory work included demonstration that 
20β-dihydrocorticosterone (20β-DHB), the murine equivalent of 20β-DHF, induced MMTV-luciferase activity 
in HEK293 cells transfected with murine GR (Supplementary Fig. S3) and is present in murine plasma and tissue 
(Supplementary Fig. S4), and that Cbr1 mRNA was higher in adipose of C57BL/6 J adult male mice fed on a high 
fat diet for 6 weeks than controls on a normal chow diet (n = 6/group) (Fig. 3B). Murine diet-induced obesity 
was therefore used as a model in which to investigate the functional role of CBR1 and 20β-dihydro metabolites. 
Groups of adult male C57BL/6 J mice (n = 12/group) maintained on a high fat diet were randomly assigned to 
groups receiving vehicle (ethanol) or Cbr1 inhibitor (quercetin, 50 μg/mouse/day, administered in drinking water 
for 6 weeks).
Quercetin lowered hepatic 20β-DHB (Fig. 6A) and increased the ratio of Cbr1 substrate (corticosterone) to 
product (20β-DHB) in liver (vehicle B: 20β-DHB ratio 0.5 ± 0.2 versus quercetin B: 20β-DHB ratio 1.6 ± 0.4, 
P = 0.01). Quercetin did not alter 20β-DHB levels in subcutaneous adipose tissue (Fig. 6B) or plasma (Fig. 6C). 
Quercetin also raised peak plasma corticosterone concentrations (Fig. 6D) but did not affect food or water intake 
or bodyweight over the course of the experiment (Fig. 6E). However, quercetin raised fasting plasma insulin 
concentrations and blood glucose during glucose tolerance tests (Fig. 6F,G). Quercetin also increased hepatic 
expression of the GR-responsive gene Period 1 (Per1), but did not alter the mineralocorticoid-responsive gene 
serum glucocorticoid kinase 1 (Sgk1) or key gluconeogenic enzyme phosphoenolpyruvate carboxykinase (Pepck) 
Figure 3. Carbonyl reductase 1 expression is increased in adipose tissue in obese horses, humans and mice. 
(A) CBR1 mRNA transcript levels are increased in visceral adipose of obese horses (n = 14/group), (B) Visceral 
adipose Cbr1 transcript levels were increased in mice on a high-fat diet for 6 weeks (n = 6/group). (C) Visceral 
adipose CBR1 transcript levels were increased in obese humans (n = 8/group). Data are mean ± SEM, *P < 0.05.
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Figure 4. 20β-Dihydrocortisol binds, translocates and activates glucocorticoid receptor inducing gene 
transcription and suppressing inflammatory gene transcription. (A) Docking of cortisol and 20β-DHF into the 
ligand binding site of GR. The automatically created pharmacophore indicates the essential structural features 
for ligand binding (red and green arrows with spheres display hydrogen-bond (H-bond) interactions and 
yellow spheres hydrophobic interactions). Amino acid residues crucial for ligand binding are shown as sticks. 
Compared to the binding interactions of cortisol 20β-DHF differs only in the hydroxyl group at the position 
20, representing a H-bond donor instead of the carbonyl group of cortisol serving as H-bond acceptor. (B) 
Unlabelled 20β-DHF displaced 3[H]-dexamethasone from GR in the lysate of SF9 cells expressing GR. (C) 1uM 
20β-DHF induced translocation of cytoplasmic GR to the nucleus of HEK293 cells within 30 minutes visualised 
by fluroescence imaging at 20x magnification. (D) 2.5uM 20β-DHF induced luciferase activation in A549 cells 
transfected with glucocorticoid responsive plasmid MMTV-luc. (E) 20β-DHF induced transcription of GR-
responsive genes IGFBP1 (EC50 0.51 µM), DUSP1 (EC50 0.32 µM), FKBP51 (EC50 0.44 µM) and GILZ (EC50 
1.25 µM) in A549 cells. (F) TNFα induced transcription of IL-1β in A549 cells, this was inhibited by cortisol and 
by 20β-DHF at 0.15 µM. Transcription was not reduced by co-incubation of cortisol or 20β-DHF with the GR 
antagonist RU486. Experiments were performed in triplicate on three occasions. Data are mean ± SEM (N = 3). 
Data were compared by two-way ANOVA and Bonferroni correction test: *P < 0.05, **P < 0.01 compared to 
vehicle.
Figure 5. 20β-Dihydrocortisol induces similar co-regulator interactions with GR as dexamethasone MARCoNI 
analysis of co-activator recruitment showed that on binding 20β-DHF, GR recruited 36% of the co-regulators 
recruited by dexamethasone. The colour of the bar represents the modulation index i.e. compound induced 
log-fold change of binding, red a positive fold change and blue a negative fold change. *P < 0.05, **P < 0.01, 
***P < 0.001 compared to the unbound receptor.
www.nature.com/scientificreports/
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in the liver (Fig. 6H). Transcript levels of Per1, adiponectin and lipoprotein lipase were not altered by quercetin 
in subcutaneous adipose tissue (Fig. 6I).
Discussion
We describe a novel pathway of glucocorticoid metabolism, whereby cortisol is converted to 20β-dihydrocortisol 
by the cytosolic enzyme CBR1, producing a metabolite which is a weak activator of GR. This pathway is 
up-regulated in adipose-tissue of obese horses, humans and mice; genetic variation in the liver predicts glucose 
dysregulation and its pharmacological inhibition alters the hypothalamic-pituitary-adrenal axis and tissue steroid 
levels in mice, with associated changes in GR-dependent gene expression and in metabolic homeostasis. This 
provides important new insights into the control of tissue glucocorticoid action and its contribution to cardio-
metabolic disease.
The glucocorticoid metabolite profile of horses, a cortisol-dominant species26, has not previously been 
described, although inter-species variation in hepatic cortisol metabolism has been reported27. 20β-DHF has 
been measured in horse urine16 and purported to be a sensitive indicator of cortisol administration, but ours are 
the first data showing 20β-DHF relative to other metabolites, and the first demonstrating 20β-DHF in plasma, 
adipose tissue and liver of horses. Predominance of 20β-DHF production occurs in other large herbivores, includ-
ing sheep28, 29. The human cortisol metabolome is more thoroughly described17, 30, and is dominated by products 
of 5α- and 5β-reduction. However, 20β-DHF has previously been identified in human urine17, 18 at levels similar 
to that of 5α-tetrahydrocortisol (5α-THF). Occasional case reports indicate urinary excretion of 20β-DHF is 
increased in human Cushing’s syndrome18, collagen disease31, rheumatoid arthritis32, hypertension19 and liver 
cirrhosis33, 34. In our study 20β-DHF was readily detectable in the plasma of healthy humans at levels equal or 
higher to that of corticosterone, but 20β-DHF represented a much smaller proportion of cortisol metabolism 
than in horses.
Figure 6. Inhibition of CBR1 in a murine model of diet-induced obesity results in increased GR activation 
and metabolic dysfunction. (A) Hepatic 20β-DHB levels were significantly lower in quercetin treated mice, 
(B) 20β-DHFB levels were not altered in subcutaneous adipose tissue, (C) plasma 20β-DHB levels were not 
altered by quercetin treatment (D) quercetin treatment resulted in increased peak plasma corticosterone 
levels. (E) Bodyweight was not different between mice in the vehicle treated group and mice treated with 
quercetin. (F,G) Quercetin-treated mice were significantly more insulin resistant and had higher fasted plasma 
insulin concentrations. (H) mRNA transcript levels of hepatic Per1 were increased in quercetin treated mice, 
(I) Adipose mRNA expression of Per1, Adiponectin (Adipq) and lipoprotein lipase (Lpl) were not altered by 
quercetin treatment. Data are mean ± SEM, n = 12/group, *P < 0.05.
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There are reports of reduction of cortisol to 20β-DHF in various human cell/tissue types including kidney and 
prostate35, gingiva36, fibroblasts37 and thrombocytes38. We found that CBR1, a ubiquitously expressed member of 
the short-chain dehydrogenase/reductase (SDR) superfamily1 catalyzes the conversion of cortisol to 20β-DHF. 
CBR1 expression is highest in tissues involved in detoxification or clearance, e.g. liver, colon, renal tubules and 
placenta39 and has been studied for its role in drug metabolism3 and as an antioxidant40. Its expression is associ-
ated with cancer, particularly lung cancer7, and reported to protect against pancreatic islet cell death41. Inhibitors 
of CBR1 have been proposed for use with chemotherapeutic agents to reduce the cardiotoxic side-effects of drugs 
such as doxorubicin4. Although glucocorticoids are known to be substrates of CBR1, the products have not been 
identified previously40. We attribute 20β-dihydro glucocorticoid generation to CBR1 since isolated CBR1 converts 
cortisol to 20β-DHF and not to other metabolites, hepatic microsomal preparations are devoid of such activity, 
and inhibition of CBR1 is sufficient to prevent 20β-DHF generation in equine liver cytosol and to lower tissue 
20β-DHB in mouse liver in vivo.
The majority of cortisol metabolites are thought to be inert and are produced to facilitate steroid excretion. 
Some metabolites, however, such as 5α-tetrahydrocorticosterone (5α-THB) bind and activate GR12. Given that 
20β-DHF was found in plasma and tissues of humans at similar levels to the endogenous glucocorticoid corti-
costerone, and is thus potentially of physiological significance, we investigated the action 20β-DHF on GR. We 
found that 20β-DHF bound GR with a lower affinity than that of cortisol but induced nuclear translocation of the 
receptor within 30 minutes, a time period comparable with cortisol. 20β-DHF induced transrepressive and trans-
activation effects after binding to GR albeit at higher concentrations than cortisol. The consequences of variation 
in CBR1 activity for GR activation are therefore hard to predict.
In human obesity, increased total cortisol production42 without consistently elevated plasma cortisol concen-
trations has been attributed to enhanced clearance of cortisol20, and in turn to increased 5α- and 5β-reductase 
and reduced 11β-HSD1 activities20. In humans, horses and mice obesity was associated with increased CBR1/
Cbr1 expression in adipose tissue, in horses with increased 20β-DHF in plasma, and in humans and horses 
with increased 20β-DHF in urine. Although 20β-DHF was not disproportionately raised in urine, total cortisol 
metabolite excretion was increased so these data are consistent with the CBR1/20β-DHF pathway contributing to 
increased cortisol clearance in obesity. Up-regulation of the CBR1 pathway in obesity was evident in adipose but 
not liver in horses and mice. In addition we did not identify any eQTL for CBR1 expression in adipose suggesting 
that this up-regulation is a functional response to obesity. This is consistent with intra-adipose inflammation and 
hypoxia in obesity, since CBR1 expression is up-regulated in response to hypoxia and inflammation via transcrip-
tion factors including Nrf2, AhR and HIF-1α43, 44. In contrast our data suggest that there are genetic influences 
on hepatic CBR1 expression in humans and that higher expression is associated with higher leptin, higher fasting 
glucose and higher HbA1c. Tissue-specific regulation of CBR1 is reported43, 45, 46 so the eQTLs we identified may, 
for example, exert their influence through liver-specific promoter(s).
To further explore the contribution of CBR1 dysregulation in obesity, we administered the Cbr1 inhibitor 
quercetin to mice with diet-induced obesity. Pharmacodynamic data suggest that quercetin inhibited corticoster-
one conversion to 20β-DHB in liver, but not in adipose tissue; this may indicate that adipose 20β-DHB is mainly 
derived from plasma rather than from local generation, or that the drug was unable to penetrate adequately into 
adipose tissue. Although an eQTL predicting higher hepatic CBR1 was associated with adverse metabolic indices, 
a paradoxical deterioration in glucose metabolism was observed when we inhibited the enzyme. This was accom-
panied by altered GR-regulated genes in liver which may be explained by the effect of substrate (corticosterone) 
accumulation or by secondary activation of the HPA axis with elevated peak plasma corticosterone resulting from 
impaired clearance. A similar phenotype and liver transcript profile occurs in mice with genetic deletion of the 
glucocorticoid-inactivating enzyme 5α-reductase type 147. Alternatively we could infer that there is a non-linear 
relationship between Cbr1 expression and effect and that an optimal cortisol/20β-DHF balance may be required 
for normal liver GR activation, such that dysregulation of Cbr1 in either direction leads to GR excess.
These findings are important since there are wide variations in CBR1 activity between individuals, in dis-
ease and after consumption of a number of naturally occurring CBR1 inhibitors: human tissue CBR1 expression 
and activity varies significantly between ethnic groups6; CBR1 expression and activity is increased in Down’s 
syndrome due to the location of the CBR1 gene on chromosome 2148; CBR1 inhibitors such as flavonoids and 
polyphenols are present in many foods and supplements49 and reported enhancers of CBR1 activity include com-
ponents of cigarette smoke7. Our data suggest the resulting variation of CBR1/20β-DHF has important conse-
quences for glucocorticoid metabolism and GR activation in health and disease.
Materials and Methods
Study design. We conducted case-control, cross-sectional or intervention studies in horses, humans, cells 
and mice. Sample sizes were chosen for 80% power to detect magnitudes of difference inferred from pilot data 
with the number of subjects and outcomes defined below or in figure legends. In vitro experiments were per-
formed in triplicate with the number of experiments and outcomes defined below and in figure legends. Details 
on inclusion and exclusion criteria for horse and human subjects are detailed below. There were no dropouts and 
no outliers were excluded.
Cortisol metabolism in horses. The first aim of the study was to characterize cortisol metabolism in lean 
and obese horses. We addressed this aim using an observational case-control study recruiting lean horses and 
obese horses that were destined for euthanasia at the Royal (Dick) School of Veterinary Studies, University of 
Edinburgh. Studies in horses were approved by the Royal (Dick) School of Veterinary Studies Ethics and Research 
committee (VERC 7014). The study was performed according to the approved ethical guidelines. The sample 
size (n = 14/group) was determined by interim analysis using total glucocorticoid metabolite excretion as the 
end-point (80% power to detect a 20% difference in groups, p < 0.05). Lean (body condition score, measure of 
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obesity ≤3/550) and obese (body condition score ≥4/5) castrated male and female horses destined for euthanasia, 
were recruited from clinics at the Royal (Dick) School of Veterinary Studies. Horses were excluded if they were 
less than 1 year old, suffering from any concurrent systemic illness or had received glucocorticoid treatment in the 
3 months prior to commencement of the study. Blood was obtained after overnight fasting, between 0900 h and 
1100 h, via an intravenous cannula inserted in the jugular vein for the purpose of euthanasia.
Horses were humanely euthanased (0900 h to 1100 h) with quinalbarbitone sodium and cinchocaine 
hydrochloride (1 mL/10Kg bodyweight; Somulose, Dechra Veterinary Products, Shrewsbury, UK). Samples of 
peri-renal adipose, liver and urine were snap frozen and stored at −80 °C.
Glucocorticoids were extracted from plasma, adipose and liver and quantified by LC-MS/MS (see supple-
mentary methods). Urinary glucocorticoids were derivatized and quantified by GC-MS/MS (supplementary 
methods). Urinary creatinine was measured by the modified Jaffe’s reaction (IL650 analyzer, Instrumentation 
Laboratories). Glucocorticoid concentrations were expressed as μg/mmol creatinine. RNA was extracted from 
adipose and liver samples for quantification of CBR1 mRNA relative to housekeeping genes SDHA and 18 s (see 
supplementary methods and supplementary Table S7).
20β-DHF in humans. In order to determine the relevance of 20β-DHF to human health and disease sam-
ples were collected from male participants at the University of Edinburgh with approval from the University 
of Edinburgh Research Ethics Committee, National Health Service Lothian Research and Development Office, 
and at Umea University with approval from the Umea Regional Ethical Review Board. The study was performed 
according to the approved ethical guidelines. Participants were required to give written informed consent prior 
to recruitment to the study. Lean individuals were defined as having a BMI <25 kg/m2 and obese individuals as 
having a BMI >25 kg/m2. Clinical details are given in supplementary Tables 2–4.
Twenty-four hour urine samples were obtained from healthy lean (n = 15) and obese (n = 18) men recruited 
as part of a separate study13. In addition, urine was collected from obese men (n = 19) with Type 2 diabetes (with 
no insulin treatment) (Supplementary Table S2). Morning fasted plasma samples were collected from healthy 
lean (n = 10) and obese (n = 10) men (Supplementary Table S3). Adipose biopsy samples for RNA extraction 
were collected from lean (n = 8) and obese (n = 8) individuals undergoing surgery (Supplementary Table S4). 
Glucocorticoids were extracted and quantified from plasma and urine as detailed in supplementary methods.
CBR1 activity in vitro. In order to determine if CBR1 could convert cortisol to 20β-DHF recombinant 
human CBR1 (Source Bioscience, Nottingham, UK) was incubated with cortisol (1 mM) and NADPH (2 mM) 
for a time course (5, 10, 20, 30, 60 and 120 minutes) at 37 °C. The reaction was stopped with the addition of ace-
tonitrile (500 µL). Deuterated cortisol (9, 11, 12, 12-[2H]4-cortisol) was added as an internal standard for quanti-
fication of cortisol and 20β-DHF. Following centrifugation (5 minutes) the supernatant was removed, dried down 
and re-suspended in mobile phase (60 µL 50:50 Methanol: water) for analysis by LC-MS/MS (Supplementary 
methods).
Interrogation of genetic data for CBR1 expression and phenotypic associations. No genetic 
variants have been robustly associated with CBR1 enzyme activity. Therefore, genetic variants that are associated 
with CBR1 transcript levels in liver were used as a surrogate for CBR1 enzymatic activity. Expression quantitative 
trait loci (eQTLs) located near to the CBR1 gene and associated with CBR1 expression in the liver were identified 
from the Stockholm-Tartu Atherosclerosis Network Engineering Task (STARNET) study. STARNET comprises 
data on 600 cases of cardiovascular disease undergoing surgical intervention with collection of multiple tissue 
types including the liver. Genome wide genotyping and tissue expression analyses including RNAseq have been 
performed22.
A two-sample Mendelian randomization approach was used to estimate the effect of CBR1 expression in the 
liver on outcomes of body mass index (BMI), body fat, and glucose and insulin sensitivity. The outcome data were 
extracted from publicly available datasets, including from GIANT and MAGIC consortia, using MR-Base23. In 
cases where outcome data were available from more than one study, the study containing all the relevant informa-
tion with the largest sample size was selected. The causal effect of CBR1 expression on the relevant outcomes was 
estimated using the Wald (or ratio) method. This method divides the coefficient from regression of the outcome 
on the genetic variant by the coefficient from regression of the exposure on the variant51; the former was derived 
from publicly available data and the latter from STARNET. This approach makes the assumption that all instru-
mental variables are valid and not subject to horizontal pleiotropy where a genetic variant affects the outcome via 
more than one biological pathway. Study overlap is a concern when undertaking two sample Mendelian random-
ization analyses. The STARNET study has not provided data to the GIANT or MAGIC consortia.
20β-DHF interaction with glucocorticoid receptor. Docking of 20β-DHF with GR. Docking studies 
were performed using the GOLD software version 5.2 (Cambridge Crystallographic Data Centre, Cambridge, 
UK)52. This software allows the identification of precise docking poses for small molecules in the binding pocket 
of a protein applying a genetic algorithm. The crystal structures with the Protein Data Bank (PDB) entry 4P6X 
[DOI:10.2210/pdb4p6x/pdb] was selected for GR. First the respective co-crystallized ligand, cortisol for GR, was 
removed from the binding pocket and re-docked into the binding site to examine whether GOLD could restore 
the original binding pose and therefore to validate the docking settings (RMSD value of 0.409 for GR). The GR 
binding sites were defined by the ligand surrounded by a 6 Å region lining the active site. GoldScore was used as 
scoring function.
Protein ligand interactions determined by the docking software were further assessed using LigandScout 3.12 
(inte:ligand GmbH, Vienna, Austria). Based on chemical functionalities, geometric distances and angles between 
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adjacent structures, this software automatically evaluates the observed binding pattern between the protein and 
the docked ligand53.
Glucocorticoid binding in SF9 cell lysates. Competitive GR binding experiments were conducted as described 
previously54. Briefly, recombinant human GRα baculovirus stock was produced using the Bac-to-Bac expression 
system and subsequently expressed in Sf9 cells according to the instructions by the manufacturer (Invitrogen, 
Carlsbad, CA). Sf9 cell lysates expressing recombinant human GR were then incubated in the presence of 
10 nM [1,2,4,6,7–3 H]-dexamethasone and unlabelled competitor (either 10 μM or 100 nM cortisol or 10 μM 
20β-DHF) for 4 h at 16 °C. Unbound ligand was separated by adding 5% dextran coated charcoal, followed by 
incubation at 4 °C for 10 min and centrifugation for 10 min at 3200 × g and 4 °C. The GR bound fraction of 
[1,2,4,6,7–3H]-dexamethasone in supernatants was measured by scintillation counting.
Experiments in cell culture. Human alveolar carcinoma cell line, A549, the human embryonic kidney cell 
line, HEK293 and the clonal line of Spodoptera frugiperda, SF9 were obtained from the European Collection of 
Cell cultures (ECACC; distributor Sigma-Aldrich Co.). Cells were grown and maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM, Lonza Group Ltd., Basel, Switzerland) supplemented with glucose (4.5 g/L), 
heat-inactivated fetal bovine serum (HI-FBS) (10% v/v), penicillin (100 IU/mL), streptomycin (100 µg/mL) and 
L-glutamine (2 mM). Cells were maintained and grown in a humidified atmosphere (95% air, 5% CO2, 37 °C). 
Unless otherwise stated cells were seeded at 2 × 105 per 35-mm well. Cells were cultured in steroid-free medium 
for 24 h prior to experimentation. Plasmids were a kind gift from K.E.Chapman, Centre for Cardiovascular 
Science, University of Edinburgh.
To study GR translocation, HEK293 cells were transfected with GR labelled with Green Fluorescent Protein 
(GFP-GR). After seeding and overnight incubation in steroid free medium, the medium was replaced with phe-
nol red free Opti-MEM (Lonza Group Ltd., Basel, Switzerland), and cells transfected using Lipofectamine 2000 
(Invitrogen, Thermo Fisher Scientific Co., Waltham, MA, USA) with 1 μg of GFP-GR plasmid. Cells were then 
treated with vehicle, cortisol (1 μM) or 20β-DHF (1 μM) and imaged using fluorescence microscopy (Nikon 
Eclipse TS100) prior to treatment and at 30, 60, 120 minutes and 4 hours.
GR activation by 20β-DHF was tested in A549 cells transiently transfected with MMTV-luciferase plasmid. 
Cells were transfected with 1 μg of pMMTV LTR–luciferase12 and 1 μg of pKC275 (encoding β-galactosidase 
as internal control) and treated with vehicle, cortisol (0.3 μM-5 μM) or 20β-DHF (0.3 μM-5 μM) for 4 hours. 
Cells were lysed and luciferase and β-galactosidase activities measured as described previously55. Galactosidase 
activity was assayed using a Tropix Kit (Applied Biosystems, Foster City, CA, USA). The mean ratio of lucif-
erase/b-galactosidase activities was calculated.
To determine effects of 20β-DHF on endogenous glucocorticoid-induced transcripts, A549 cells were incu-
bated in the presence of increasing concentrations of either cortisol, 20β-DHF (0.15 μM-5 μM) or vehicle (etha-
nol) for 4 hours. RNA was extracted and RT-qPCR used to quantify DUSP1 (dual specificity phosphatase 1), GILZ 
(glucocorticoid-induced leucine zipper), IGFBP1 (insulin-like growth factor binding protein 1) and of FKBP51 
(FK506-binding protein 51) relative to 18 S (see supplementary Table S6 for primer design and supplementary 
methods). To determine the effects of 20β-DHF on inflammatory transcripts cells were pre-incubated with vehi-
cle or TNFα (10 ng/mL) for 1 hour before a further 4 hours in the presence of vehicle, cortisol or 20β-DHF 
(0.15 μM–5 µM). RNA was extracted and IL-1β (interleukin 1β) mRNA quantified relative to 18S.
MARCoNI analysis of 20β-DHF binding to GR. A microarray Assay for Real-time Co-regulator-Nuclear 
Receptor Interaction (MARCoNI) was used to compare the quantitative and qualitative co-regulator recruitment 
induced when 20β-DHF (1 μM) binds with GR with that of recruitment in response to dexamethasone (1 μM) 
using a previously described method22, 56.
Pharmacological inhibition of CBR1 in vivo. For in vivo studies in mice, experiments were approved 
by the University of Edinburgh ethical committee and performed under the Provisions of the Animals Scientific 
Procedures Act (1986) of the UK Home Office, in accordance with EU Directive 2010/63. Male C57BL/6 J mice 
aged 8 weeks were purchased from Harlan laboratories and used to conduct a randomized vehicle controlled 
experiment. Mice were randomly assigned to the vehicle (n = 12) or quercetin-treatment group (n = 12). All 
the mice were fed ad-lib high-fat diet (D12331, Research Diets inc., New Jersey, USA) for 6 weeks. Quercetin 
treatment was administered in drinking water (50 μg/mouse/day57). Bodyweight, food and water intake were 
monitored weekly. At week 6 blood collected from tail nick at 0800 h and at 2000h for analysis of plasma basal cor-
ticosterone by Enzo Corticosterone EIA Kit (Enzo Life Sciences, Exeter, UK). Mice were fasted for 6 h (0800–1400 
h) in clean cages before undergoing a glucoses tolerance test (GTT). Glucose (2 mg/g body weight, 40% w/v in 
saline) was administered via intraperitoneal injection. Blood was collected from tail nick immediately prior to 
injection, 15, 30, 60, and 90 minutes after injection. Glucose was measured immediately using a point-of-care 
glucometer. Plasma insulin was measured using the Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem, Inc., 
IL, USA). Seven days after the GTT animals were culled by decapitation. Plasma was extracted from trunk blood 
and stored at −20 °C. Tissue was extracted and stored at −80 °C. mRNA and glucocorticoid extraction and quan-
tification are described in supplementary methods (see Supplementary Table S8 for murine primer sequences).
Statistical analysis. For horse, human and mouse studies data were tested for normality by 
Kolmogorov-Smirnov test and subsequent comparisons (lean v obese) performed using unpaired Student’s t-tests 
or Mann-Whitney U test. For cell-based studies with changing steroid concentrations comparisons (20β-DHF v 
cortisol) were performed using two-way ANOVA with Bonferroni post-hoc tests. Statistical significance was set 
at P < 0.05.
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